Bernstein raised the firm’s price target on Eli Lilly (LLY) to $1,300 from $1,100 and keeps an Outperform rating on the shares. The firm cites a catalyst path and earnings upside over the next 24 months-plus driven by Orforglipron launch, Trump GLP1 deal and ex-U.S. expansion.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY: